- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bharat Biotech Covaxin rolling data to start in July: WHO
Hyderabad: Taking the approval process ahead, World Health Organisation (WHO) which is currently approached by Bharat Biotech for an Emergency Use Listing of its COVID-19 vaccine Covaxin, has said pre-submission meeting for it was held and the "Rolling Data will starting in July."
The information was provided in the WHO website in the Status of COVID-19 vaccines within WHO EUL-PQ evaluation process document. Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, WHO guidelines said.
Meanwhile, stating that its COVID-19 vaccine Covaxin adheres to international standards, Bharat Biotech''s joint managing director Suchitra Ella on Tuesday said external timelines are in the company's hands.
"Covaxin will cross new frontiers, adhering highest international regulatory guidelines. A new vaccine from (India) is all set to make history once again, with proven data, safety & quality. We stand committed to deliver no matter what, external timelines not in our control," Ella tweeted.
Her tweet assumes significance in the wake of the company trying to get EUL from the WHO even as its US partner Ocugen preparing to get US Food and Drug Administrations nod to use the jab in that country.
Read also: Bharat Biotech, WHO pre-submission meeting for Covaxin EUL on June 23
Ella also tweeted a table of states and cities in which Covaxin is currently available.
It said the jab is used in 27 cities in 18 states.
Read also: Reports on submitting Covaxin phase 3 data to WHO incorrect, lack any evidence: Bharat Biotech
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751